BioMarin Provides Program Update on Vosoritide in Achondroplasia
April 20, 2016 10:36 ET
|
BioMarin Pharmaceutical Inc.
New Data Shows Durable and Consistent Effects on Mean Annualized Growth Velocityfor up to 12 months with Increases of 46%-65% from Baseline Phase 3 Randomized Controlled Study Planned to Start at...
BioMarin Provides Encouraging Preliminary Data on First 8 Patients in Hemophilia A Gene Therapy Program
April 20, 2016 08:30 ET
|
BioMarin Pharmaceutical Inc.
Two High Dose Patients Show Increasing Levels of Factor VIII Above 50% Five of Six High Dose Patients Show Factor VIII Levels Above 5% SAN RAFAEL, Calif., April 20, 2016 (GLOBE NEWSWIRE) -- ...
BioMarin to Highlight Breadth of Innovative Development Pipeline at R&D Day on April 20th in New York
April 18, 2016 08:30 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., April 18, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) will host an R&D Day from 8am (ET) to 12pm (ET) on Wednesday, April 20, 2016 in New York City....
BioMarin Receives European Orphan Drug Designation for BMN 270, First Investigational AAV-Factor VIII Gene Therapy for Patients with Hemophilia A
March 24, 2016 08:30 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., March 24, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that BMN 270, an investigational gene therapy for the treatment of hemophilia A,...
BioMarin to Attend Three Upcoming Investor Conferences in March
March 03, 2016 08:30 ET
|
BioMarin Pharmaceutical Inc.
- Cowen and Company 36th Annual Health Care Conference on March 8 in Boston - Raymond James 37th Annual Institutional Investors Conference on March 9 in Orlando ...
BioMarin Announces Positive Data From Cerliponase Alfa Program for Treatment of CLN2 Disease, a Form of Batten Disease, at 12th Annual WORLDSymposium(TM) 2016
March 02, 2016 19:05 ET
|
BioMarin Pharmaceutical Inc.
80% Reduction in Clinical Disease Progression in One Year Compared to Natural History (p <0.0001) Company Plans to Submit Marketing Applications Starting Mid-Year 2016 SAN RAFAEL, Calif., March...
BioMarin Receives Orphan Drug Designation From FDA for First AAV-Factor VIII Gene Therapy, BMN 270, for Patients With Hemophilia A
March 01, 2016 17:42 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., March 01, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that BMN 270, an investigational gene therapy for the treatment of patients with...
BioMarin Announces BioMarin RareConnections(TM) Rebranding and Consolidating BioMarin’s Comprehensive Support and Services for Eligible Rare Disease Patients
February 29, 2016 08:30 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., Feb. 29, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the launch of BioMarin RareConnectionsTM, rebranding its patient-focused offering...
BioMarin Announces 21 Presentations at 12th Annual WORLDSymposium™ 2016 February 29-March 4 in San Diego, California: 6 Oral and 15 Poster
February 29, 2016 08:25 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., Feb. 29, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company will present data in six oral and 15 poster presentations at the...
BioMarin Announces Fourth Quarter and Full Year 2015 Financial Results
February 25, 2016 16:02 ET
|
BioMarin Pharmaceutical Inc.
- Full-year 2015 Total BioMarin Revenue Increases 18.8% to $889.9 million Year-over-Year - Vimizim Net Product Revenue Contributes Over $228 million to 2015 Top-line - Full-year 2016 Total...